Harte Hanks (HHS) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
8 Aug, 2025Executive summary
Q2 2025 revenue was $38.6 million, down 14.2% year-over-year, with declines across all segments due to customer turnover and cautious client spending.
Net loss for Q2 2025 was $0.3 million ($0.05/share), a significant improvement from a $27.8 million ($3.84/share) loss in Q2 2024, which included large pension termination charges.
Project Elevate transformation program continued, targeting $16 million in cost savings through 2027, with $1.0 million in restructuring charges recorded YTD.
Positive EBITDA of $1.1 million and adjusted EBITDA of $1.5 million reflect operational discipline and a debt-free balance sheet.
Project Elevate and cost controls remain central to the multi-year transformation strategy.
Financial highlights
Operating income for Q2 2025 was $34,000, down from $1.4 million in Q2 2024; operating margin fell to 0.1% from 3.0%.
Adjusted operating income was $403,000, with an adjusted operating margin of 1.0% versus 5.6% last year.
Cash and cash equivalents were $4.8 million at June 30, 2025, rising to $9.9 million by July 31, 2025.
No borrowings outstanding under the $25 million credit facility; $24 million available after letters of credit.
Net loss per share was $(0.05) for Q2 2025, compared to $(3.84) in Q2 2024.
Outlook and guidance
Management expects to meet liquidity needs for the next twelve months and beyond, with no substantial doubt about going concern.
Further cost reductions are anticipated as Project Elevate progresses, with restructuring charges expected to total $10.1 million through 2025.
Focus remains on operational efficiencies, new customer acquisition, and expanding client relationships to support long-term profitability.
Strong cash position and zero-debt profile provide opportunities for investment in growth and shareholder value initiatives.
Latest events from Harte Hanks
- All director nominees, Say on Pay, and auditor ratification proposals were approved by majority vote.HHS
AGM 2026 - Revenue fell 10.3% and net loss widened, but strong liquidity supports a positive outlook.HHS
Q1 2026 - Operational improvements, governance enhancements, and key votes position the company for growth.HHS
Proxy filing - Positive EBITDA and improved net results in FY 2025 despite lower revenue and segment declines.HHS
Q4 2025 - Shareholders to vote on board, executive pay, and auditor as company targets growth and innovation.HHS
Proxy Filing - Beneficial ownership update adds Rosenbachs as 26.26% holders for 2025 meeting.HHS
Proxy Filing - Q3 2025 revenue dropped 17% with net loss, but cost controls and new deals support outlook.HHS
Q3 2025 - Q3 revenue up 1.1% YoY; profit metrics declined; Q4 revenue expected to contract.HHS
Q3 2024 - Q2 net loss of $27.8M from pension charge; Sales Services surged, cash strong, no debt.HHS
Q2 2024